Active substance
Paroxetine
- SFDA 15
- US FDA 36
- Health Canada 51
- US price lines 16
- NHS prices 4
- WHO EML 1
- Safety 21
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AXOR 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 48.85 | Generic · Prescription | EVA PHARMA | Valid |
| AXOR 30 mg film-coated tablet | 30 mg | Film-coated tablet · Oral use | 30 Blister | SAR 60.10 | Generic · Prescription | EVA PHARMA | Valid |
| AXOR 40 mg film-coated tablet | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 80.15 | Generic · Prescription | EVA PHARMA | Valid |
| PADO 20MG FILM COATED TABLET | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 31.40 | Generic · Prescription | UNITED PHARMACEUTICAL CO. | Valid |
| PAROXAT 10 MG F-C TABLETS | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 30.15 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| PAROXAT 20 MG F-C TABLETS | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 60.30 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| PAROXAT 30MG F-C TABLETS | 30 mg | Film-coated tablet · Oral use | 30 Blister | SAR 78.25 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| PAXITAB 20MG TABLET | 20 mg | Tablet · Oral use | 30 Blister | SAR 54.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| PAXITAB 40MG TABLET | 40 mg | Tablet · Oral use | 30 Blister | SAR 89.05 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| Parlotin | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 15.20 | Generic · Prescription | BLUEPHARMA GENERICOS,COMERCIO DE MEDICAMENTOS , S.A. | Valid |
| SEROXAT 20MG TABLETS | 20 mg | Tablet · Oral use | 30 Blister | SAR 60.30 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| SEROXAT CR 12.5MG TABLETS | 12.5 mg | Tablet · Oral use | 30 Blister | SAR 61.90 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
| SEROXAT CR 25MG TABLETS | 25 mg | Tablet · Oral use | 30 Blister | SAR 82.30 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
| SEROXAT CR 12.5 MG TABLETS | 12.5 mg | Tablet · Oral use | 30 Blister | SAR 93.85 | NCE · Prescription | SMIITHKLINE BEECHAM | Withdrawn by MAH · Not Marketed |
| SEROXAT CR 25 MG TABLETS | 25 mg | Tablet · Oral use | 30 Blister | SAR 159.05 | NCE · Prescription | SMIITHKLINE BEECHAM | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ABDOMINAL SPASM; ACUTE BIPOLAR I DEPRESSION; ALZHEIMER / DEMENTIA; ANXIETY DISORDERS; ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD); DEPRESSION; FIBROMYALGIA; HUNTINGTON'S DISEASE-TICS; IRRITABLE BOWEL SYNDROME; MENOPAUSE; MENSTRUAL DISORDERS; NEUROPATHIC PAIN; PAIN MANAGEMENT IN CANCER PATIENTS; POLYCYTHEMIA VERA - PRURITUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PAXIL | EQ 10MG BASE; EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE | tablet · oral | APOTEX | Prescription | 29 Dec 1992 |
| PAXIL CR | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE | tablet, extended release · oral | APOTEX | Prescription | 16 Feb 1999 |
| PAROXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE | tablet · oral | APOTEX | Prescription | 30 Jul 2003 |
| PAROXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE | tablet · oral | CHARTWELL RX | Prescription | 15 Aug 2005 |
| PAROXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE | tablet · oral | ZYDUS PHARMS USA | Prescription | 7 Mar 2007 |
| PAROXETINE HYDROCHLORIDE | EQ 12.5MG BASE; EQ 25MG BASE | tablet, extended release · oral | AUROBINDO PHARMA USA | Prescription | 29 Jun 2007 |
| PAROXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE | tablet · oral | AUROBINDO PHARMA | Prescription | 25 Jul 2007 |
| PAROXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE | tablet · oral | MYLAN | Prescription | 13 Mar 2008 |
| PAROXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE | tablet · oral | OXFORD PHARMS | Prescription | 21 Jun 2010 |
| PAROXETINE HYDROCHLORIDE | EQ 37.5MG BASE | tablet, extended release · oral | AUROBINDO PHARMA USA | Prescription | 14 Apr 2011 |
| BRISDELLE | EQ 7.5MG BASE | capsule · oral | LEGACY | Prescription | 28 Jun 2013 |
| PAROXETINE | EQ 10MG BASE; EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE | tablet · oral | PRINSTON INC | Prescription | 31 Oct 2014 |
| PAROXETINE HYDROCHLORIDE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE | tablet, extended release · oral | LANNETT CO INC | Prescription | 10 Jun 2016 |
| PAROXETINE MESYLATE | EQ 7.5MG BASE | capsule · oral | ACTAVIS LABS FL INC | Prescription | 20 Jun 2017 |
| PAROXETINE MESYLATE | EQ 7.5MG BASE | capsule · oral | PRINSTON INC | Prescription | 18 Aug 2017 |
| PAROXETINE HYDROCHLORIDE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE | tablet, extended release · oral | SCIECURE PHARMA INC | Prescription | 12 Jun 2018 |
| PAROXETINE HYDROCHLORIDE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE | tablet, extended release · oral | CSPC OUYI | Prescription | 16 Feb 2021 |
| PAROXETINE HYDROCHLORIDE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE | tablet, extended release · oral | CADILA PHARMS LTD | Prescription | 27 Aug 2021 |
| PAROXETINE HYDROCHLORIDE | EQ 10MG BASE/5ML | suspension · oral | NOVITIUM PHARMA | Prescription | 3 Sep 2021 |
| PAROXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE | tablet · oral | YILING | Prescription | 2 Nov 2021 |
| PAROXETINE HYDROCHLORIDE | EQ 12.5MG BASE; EQ 25MG BASE | tablet, extended release · oral | PRINSTON INC | Prescription | 4 Jan 2024 |
| PAROXETINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 12.5MG BASE | tablet, extended release · oral | ALEMBIC | Prescription | 24 Sep 2025 |
| PAROXETINE HYDROCHLORIDE | EQ 10MG BASE/5ML | suspension · oral | ANNORA PHARMA | Prescription | 5 Mar 2026 |
| PAXIL | EQ 50MG BASE | tablet · oral | APOTEX | Discontinued | 29 Dec 1992 |
| PAXIL | EQ 10MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | suspension · oral | APOTEX | Discontinued | 25 Jun 1997 |
11 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-PAROXETINE TABLETS | 02510480 | 10 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-PAROXETINE TABLETS | 02510499 | 20 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-PAROXETINE TABLETS | 02510510 | 30 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| APO-PAROXETINE | 02240907 | 10 MG | TABLET · ORAL | APOTEX INC |
| APO-PAROXETINE | 02240908 | 20 MG | TABLET · ORAL | APOTEX INC |
| APO-PAROXETINE | 02240909 | 30 MG | TABLET · ORAL | APOTEX INC |
| AURO-PAROXETINE | 02383276 | 10 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-PAROXETINE | 02383284 | 20 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-PAROXETINE | 02383292 | 30 MG | TABLET · ORAL | AURO PHARMA INC |
| BIO-PAROXETINE | 02444909 | 10 MG | TABLET · ORAL | BIOMED PHARMA |
| BIO-PAROXETINE | 02444917 | 20 MG | TABLET · ORAL | BIOMED PHARMA |
| BIO-PAROXETINE | 02444925 | 30 MG | TABLET · ORAL | BIOMED PHARMA |
| JAMP PAROXETINE TABLETS | 02507773 | 10 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP PAROXETINE TABLETS | 02507781 | 20 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP PAROXETINE TABLETS | 02507803 | 30 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| M-PAROXETINE | 02467402 | 10 MG | TABLET · ORAL | MANTRA PHARMA INC |
| M-PAROXETINE | 02467410 | 20 MG | TABLET · ORAL | MANTRA PHARMA INC |
| M-PAROXETINE | 02467429 | 30 MG | TABLET · ORAL | MANTRA PHARMA INC |
| MAR-PAROXETINE | 02411946 | 10 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-PAROXETINE | 02411954 | 20 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-PAROXETINE | 02411962 | 30 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MINT-PAROXETINE | 02421372 | 10 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-PAROXETINE | 02421380 | 20 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-PAROXETINE | 02421399 | 30 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| NRA-PAROXETINE | 02479753 | 10 MG | TABLET · ORAL | NORA PHARMA INC |
26 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PAROXETINE CR 12.5 MG TABLET | $0.52008 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE CR 25 MG TABLET | $0.38562 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE CR 37.5 MG TABLET | $0.3974 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE ER 12.5 MG TABLET | $0.52008 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE ER 25 MG TABLET | $0.38562 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE ER 37.5 MG TABLET | $0.3974 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE HCL 10 MG TABLET | $0.06189 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE HCL 10 MG/5 ML SUSP | $1.40007 | per ML | 23 Sep 2026 |
| US NADAC | PAROXETINE HCL 20 MG TABLET | $0.06108 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE HCL 30 MG TABLET | $0.09543 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE HCL 40 MG TABLET | $0.09655 | per EA | 23 Sep 2026 |
| US NADAC | PAROXETINE MESYLATE 7.5 MG CAP | $2.62233 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Paroxetine 10mg tablets | £1.02 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Paroxetine 20mg tablets | £1.21 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Paroxetine 30mg tablets | £1.45 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Paroxetine 40mg tablets | £6.40 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 24.3. Medicines for anxiety disorders · core (EML); complementary (EMLc)
Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
Safety signals and safety-related labeling changes
- US FDA 23 Sep 2026 PAXIL — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Sep 2026 PAXIL — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Sep 2026 PAXIL CR — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Feb 2025 BRISDELLE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Aug 2023 PEXEVA — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 29 Sep 2022 PRAC signal: Pulmonary hypertension
Action for MAH: update of the product information: No - EMA PRAC 10 Mar 2022 PRAC signal: Pulmonary hypertension
Action for MAH: update of the product information: No - EMA PRAC 1 Oct 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: Yes - EMA PRAC 11 Jun 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No - EMA PRAC 12 Mar 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No - EMA PRAC 12 Mar 2020 PRAC signal: Microscopic colitis
Action for MAH: update of the product information: Yes - EMA PRAC 31 Oct 2019 PRAC signal: Microscopic colitis
Action for MAH: update of the product information: No - EMA PRAC 16 May 2019 PRAC signal: Persistent sexual dysfunction after drug withdrawal
Action for MAH: update of the product information: Yes - EMA PRAC 31 Oct 2018 PRAC signal: Persistent sexual dysfunction after drug withdrawal
Action for MAH: update of the product information: No - EMA PRAC 6 Sep 2018 PRAC signal: Persistent sexual dysfunction after drug withdrawal
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.